CROWD-COMPARE

Phase 1

• Conditions: Heart Failure; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: CTIS2022-503010-23-01
• Lead Sponsor: Odense University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-08
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 5600

Inclusion Criteria

Patients who are registered in the Danish Heart Failure Registry with reduced ejection fraction who have claimed at least one prescription for either Carvedilol or Metoprolol succinate.

Exclusion Criteria

Patients who have filled in a prescription for Carvedilol or Metoprolol succinate before the date of first registered visit in the Danish Heart Failure Registry and patients who have opted out of the study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The objective of CROWD-COMPARE is to compare the efficacy of Carvedilol and Metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients followed in a heart failure clinic, who have an indication for treatment with beta-blockers due to heart failure with reduced ejection fraction.;Secondary Objective: None;Primary end point(s): The primary endpoint will be a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s):1) All-cause mortality. 2) A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter).